Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZTOUND: ASTX030 in Myeloid Neoplasms and AML
NCT04256317Phase 3Recruiting
- Sponsor
- Taiho Oncology
- Start
- May 2020
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of cedazuridine + azacitidine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and 1 more (6 arms), sponsored by Taiho Oncology. Primary endpoints: Area Under the Curve From 0 to 24 Hours, Treatment-emergent Adverse Events at 36 months and 2 more. Started May 2020; status: recruiting.
02
Drugs
cedazuridine + azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT04256317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256317.